Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 14/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13467436 | 1.00 | SLC9A3 (0.73) | SLC9A3 | |
| SCHEMBL16887458 | 0.98 | SLC9A3 (0.75) | SLC9A3 | |
| SCHEMBL16638580 | 0.98 | SLC9A3 (0.75) | SLC9A3 | |
| SCHEMBL16638568 | 0.96 | SLC9A3 (0.72) | SLC9A3 | |
| SCHEMBL15267574 | 0.96 | SLC9A3 (0.72) | SLC9A3 | |
| SCHEMBL16479046 | 0.95 | SLC9A3 (0.71) | SLC9A3 | |
| SCHEMBL20404651 | 0.95 | SLC9A3 (0.74) | SLC9A3 | |
| SCHEMBL16479009 | 0.95 | SLC9A3 (0.71) | SLC9A3 | |
| SCHEMBL20404648 | 0.95 | SLC9A3 (0.71) | SLC9A3 | |
| SCHEMBL24380137 | 0.95 | SLC9A3 (0.70) | SLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | SLC9A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.